SI-BONE, Inc. - 1781346 - SI-BONE INC

Explicit Guidance:

• No specific financial guidance: Management explicitly declined to provide revenue, earnings, or growth guidance for 2027, deferring comments until after observing fourth-quarter performance and early 2027 trends.
• Gross Margins: Expected to dip to approximately 78% temporarily with new product launches (e.g., Onyx) due to non-cash depreciation, with a roadmap to return to industry-leading levels of ~80%.
• Cash Flow: Targeting cash flow break-even status; profitability is described as growth-driven, transitioning from negative EBITDA to cash flow break-even.
• Product Cadence: Commitment to launch at least one, potentially two products annually targeting new Standard Addressable Markets (SAMs).

Business-Segment Outlook:

• Onyx (New Platform):
  • Market Size: Estimated 200,000 annual procedures globally; 40,000 in deformity and 150,000–180,000 in degenerative (DGEN) fusion.
  • Adoption Strategy: Launching via an alpha program; transitioning to beta in Q4, with a full launch in Q1 followed by surgical capacity rollouts through the first half of the year.
  • Commercial Ramp: Anticipated strong ramp into 2027–2028, leveraging existing Granite customer base (700+ physicians) and hybrid sales force.
  • ASP/Product per Case: Deformity cases target 4 Onyx implants ($12,000 value); Degenerative cases target 2 implants ($6,000 value).
• SI Joint Dysfunction:
  • Market Size: Remains the largest revenue contributor with 280,000 procedures annually.
  • Growth Drivers: Expansion into interventional spine physicians and new sites of service (ASCs, in-office).
  • Reimbursement: New CPT code 27279 finalized for in-office performance at $20,000 reimbursement, creating durable growth runway.
• Granite & Complex Fusion:
  • Clinical Data: Paula study data expected soon showing revision rates dropping from 24% to 3% (device-specific <1%).
  • Volume Potential: UIV/LIV failure rates estimated at 27–30%; expected to capture significant share via clinical evidence.

Market and Competitive Outlook:

• Strategic Positioning: Shifting narrative from single-product entity to a technology platform focused on unmet clinical needs in compromised bone (osteoporosis/osteopenia), avoiding "me-too" competition.
• Reimbursement Inflection: New DRGs effective October 1st are permanent and expected to drive commercial coverage adoption within 12 months, increasing reimbursement by $20,000–$50,000 for pelvic fixation.
• Market Expansion: Targeting interventional spine physicians and ASCs/in-office settings to capture incremental volume rather than cannibalizing hospital-based surgeons.
• Competitive Moat: Focusing on high-failure-rate procedures where clinical outcomes (reduced revision) drive demand independent of reimbursement barriers.

Macro / Industry Outlook:

• Reimbursement Environment: Management views current DRG and CPT code changes as durable and permanent tailwinds, not one-off events.
• Supply Chain & Operations: Focus on optimizing asset efficiency and inventory turns to maintain gross margins despite new product complexity.
• Sales Force: Hybrid model (field + agents) optimized for productivity ($2.3M revenue per rep); no significant attrition risks anticipated due to strong growth trajectory.

Strategic Initiatives:

• Onyx Launch: Full commercial rollout in Q1, with surgical capacity scaling through Q2 to support Q4 2027 activation of NTAP.
• NTAP (New Technology Add-on Payment): Filed for Onyx; expected to go effective October 1, 2027, with an estimated 12-month runway post-approval.
• Partnerships: Collaboration with Smith & Nephew in the trauma segment to allow internal reps to focus on high-growth SI joint and fusion areas.
• Sales Force Expansion: "Surgical approach" to hiring, adding senior and junior reps market-by-market to increase bandwidth for hunting new accounts.
• Innovation Pipeline: Operating on an "innovation supercycle" with a roadmap to bring multiple products to market over the next 5 years targeting compromised bone.

Risks and Headwinds to Outlook:

• Execution Timing: Ramp of new products and surgical capacity may take time; management expects a gradual build rather than immediate inflection.
• Clinical Data Dependency: While early adopters may drive initial sales, long-term adoption by conservative physicians depends on upcoming clinical study data for Onyx.
• Reimbursement Lag: Commercial payer uptake of new DRGs is expected over the next 12 months, potentially slowing the full financial impact.
• Patent Expiry: A key patent (triangle) expiring in 2028 remains a concern, though management argues the platform shift mitigates this risk.
• New Product Dilution: Initial gross margin dilution to ~78% until cost-out measures and volume efficiencies are realized.

Management Tone on the Future:

• Confidence Level: High; management expresses strong conviction in the product-market fit, citing Onyx's alpha performance matching or exceeding Granite's initial launch metrics.
• Outlook: Optimistic about a "flywheel" effect, expecting 2027 and 2028 to be transformational years driven by the convergence of new products (Onyx), reimbursement tailwinds (DRGs/NTAP), and site-of-care expansion.
• Strategic Patience: Deliberate refusal to guide on specific 2027 numbers to ensure expectations are grounded in realized Q4 and early Q1 performance, emphasizing "one step at a time."
• Investor Narrative: Explicitly aiming to shift investor perception from a single-disease state company to a scalable, multi-platform technology leader.

Miscellaneous:

• Salesforce Productivity: Revenue per rep has grown from < $1.4M (4 years ago) to $2.3M, validating the hybrid sales model.
• Clinical Evidence Strategy: Commitment to publishing clinical studies to support adoption across three physician buckets: early adopters, wait-and-see, and data-driven prescribers.
• Geographic/Channel Focus: Primarily U.S. market with specific focus on KOLs, academic centers, and VAC committee approvals facilitated by existing Granite infrastructure.